Alpelisib as a new treatment option for patients with the PIK3CA mutation. The effectiveness and tolerability of therapy on the example of a clinical case
The PI3K / AKT / mTOR pathway plays a key role in the regulation of cell proliferation, growth and survival. It was found that the PIK3CA mutation, an oncogene encoding the catalytic isoform of PI3K kinase p110α, is one of the most frequent somatic mutations in breast cancer: it is found in about 20...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-06-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6216 |
| Summary: | The PI3K / AKT / mTOR pathway plays a key role in the regulation of cell proliferation, growth and survival. It was found that the PIK3CA mutation, an oncogene encoding the catalytic isoform of PI3K kinase p110α, is one of the most frequent somatic mutations in breast cancer: it is found in about 20-50% of all cases, most often in the ER + HER2 subtype. Studies have shown that the presence of the PIK3CA mutation is associated with an increased risk of recurrence, progression, or death. A deeper understanding of the role of the PIK3CA mutation in the growth and survival of cancer cells has led to the development of targeted therapeutic agents aimed at directly inhibiting the PI3K pathway. Alpelisib is the only PI3K inhibitor to date that has successfully passed clinical trials and is approved for the treatment of ER + HER2– metastatic breast cancer in patients with the PIK3CA mutation who have previously received hormonal therapy. The article presents a clinical case of treatment with Alpelisib, discusses in detail the issues of drug efficacy, including after CDK 4/6 inhibitors, as well as tolerance and management of adverse events. Alpelisib not only expands the treatment options for patients with the PIK3CA mutation, but is also a clear example of therapy personalization. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |